A real-world study evaluating drug tolerability and health care resource use with acalabrutinib vs ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma
In R/R CLL/SLL, acalabrutinib demonstrated a more favorable cardiovascular safety profile than ibrutinib, with fewer HTN events and CV MEOIs. This translated into reduced hospital admissions and lower HCRU, supporting acalabrutinib as a potentially better tolerated long-term treatment option in community practice.
Authors
- Aaron Peevyhouse
- Mayur Subhash Narkhede (ORCID: https://orcid.org/0000-0002-2606-0533)
- Vikram Shetty (ORCID: https://orcid.org/0000-0003-0685-1669)
- Svea K. Wahlstrom
- Daniel A. Ermann (ORCID: https://orcid.org/0000-0001-9233-294X)
- Sibel Blau
- Lee Ann Dietz
- Heather Neuhalfen
- Samantha L. Thompson
- George Dranitsaris
- Anna Teschemaker
- Chanh Huynh
Institutions
- University of Utah (US)
- Cancer Care Ontario (CA)
- Alliance for Clinical Trials in Oncology (US)
- University of Alabama at Birmingham (US)
- AstraZeneca (Brazil) (BR)
- Syracuse University (US)
Publication Details
- Journal
- Journal of Medical Economics
- Published
- 2025-12-27
- DOI
- https://doi.org/10.1080/13696998.2025.2604971
- Primary Topic
- Chronic Lymphocytic Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00